Research Analysts Issue Forecasts for Urogen Pharma Ltd’s FY2022 Earnings (URGN)

Urogen Pharma Ltd (NASDAQ:URGN) – Equities researchers at Jefferies Group issued their FY2022 earnings per share (EPS) estimates for Urogen Pharma in a report released on Tuesday. Jefferies Group analyst M. Andrews forecasts that the company will post earnings of $0.70 per share for the year.

Several other research analysts also recently issued reports on URGN. Zacks Investment Research upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, October 18th. Cowen reissued a “buy” rating on shares of Urogen Pharma in a report on Wednesday, November 15th. UBS Group cut shares of Urogen Pharma from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 15th. Raymond James Financial cut shares of Urogen Pharma from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 15th. Finally, Oppenheimer set a $51.00 target price on shares of Urogen Pharma and gave the company an “outperform” rating in a report on Tuesday, November 14th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $39.00.

Shares of Urogen Pharma (NASDAQ:URGN) traded down $0.42 during midday trading on Wednesday, hitting $49.58. 127,000 shares of the stock traded hands, compared to its average volume of 151,377. Urogen Pharma has a 52-week low of $13.01 and a 52-week high of $56.56.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.10).

In other news, major shareholder Proquest Investments Iv, L.P. sold 209,298 shares of the firm’s stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $40.60, for a total value of $8,497,498.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Institutional investors and hedge funds have recently made changes to their positions in the business. Consonance Capital Management LP acquired a new position in shares of Urogen Pharma during the 4th quarter valued at about $34,101,000. FMR LLC purchased a new stake in shares of Urogen Pharma during the second quarter worth approximately $13,892,000. Menora Mivtachim Holdings LTD. increased its stake in shares of Urogen Pharma by 341.4% during the third quarter. Menora Mivtachim Holdings LTD. now owns 569,589 shares of the company’s stock worth $17,953,000 after buying an additional 440,534 shares during the period. DSAM Partners London Ltd boosted its holdings in Urogen Pharma by 83.2% in the fourth quarter. DSAM Partners London Ltd now owns 136,500 shares of the company’s stock valued at $5,079,000 after purchasing an additional 62,000 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Urogen Pharma by 412.1% in the fourth quarter. Renaissance Technologies LLC now owns 131,100 shares of the company’s stock valued at $4,878,000 after acquiring an additional 105,500 shares during the period. 32.63% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/14/research-analysts-issue-forecasts-for-urogen-pharma-ltds-fy2022-earnings-urgn.html.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Earnings History and Estimates for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply